INTRODUCTION {#S1}
============

Regulation of gene expression in eukaryotes is an extremely complex process^[@R1]^. *Cis*-regulatory sequences on promoters and enhancers of target genes facilitate the cooperative assembly of transcriptional regulatory complexes^[@R1]^. In addition, multiple signaling cascades contribute to more elaborate regulation of gene expression by post-translational modifications of transcriptional factors (TFs)^[@R2]^. In spite of recent breakthroughs in high-resolution methods for studies of TFs genomics, the details of TFs partnerships, especially with contributions of post-translational modifications, are poorly understood due to insufficient structural data^[@R1]^. Ets1•Runx1 partnership provides a perfect basis for filling the gap. The two TFs regulate *T cell receptor alpha* (*TCR*α) and a variety of other genes via binding to a composite Ets1•Runx1 sequence^[@R3]-[@R7]^.

Ets1 transcription factor participates in embryonic development, lymphoid differentiation, proliferation, apoptosis and angiogenesis^[@R8]^. It is amplified and rearranged in a variety of cancers.^[@R9]^ DNA binding of Ets1 is regulated by an inhibitory serine rich region (SRR) and inhibition regulatory module (IRM) flanking its DNA-binding Ets domain (ED) ([Fig. 1a](#F1){ref-type="fig"})^[@R10]^. IRM comprises of inhibitory helices HI1 and HI2 N-terminal to the ED and H4 and H5 C-terminal to ED^[@R11],\ [@R12]^. The IRM and the SRR interact with the ED, resulting in a 40-fold reduction in DNA binding affinity.^[@R13]^ DNA binding of Ets1 is also regulated by an Ca^2+^ signaling-mediated phosphorylation of the serines in SRR^[@R13]-[@R15]^. Partner proteins activate Ets1 and among them is a Runx1 transcription factor. Runx1 acts by targeting the IRM of Ets1 via direct physical interaction between the two proteins^[@R4],\ [@R10],\ [@R16],\ [@R17]^.

Runx1 is required for definitive hematopoiesis and is well-known for its frequent chromosomal translocations and point mutations in leukemia^[@R18]^. DNA binding of Runx1 is auto-inhibited by sequences flanking its DNA-binding Runt domain (RD) ([Fig. 1a](#F1){ref-type="fig"})^[@R16],\ [@R17]^. Core binding factor β (CBFβ) binds RD and enhances Runx1 DNA binding without interacting with DNA^[@R19]^. In contrast, the Runx1•Ets1 cooperation requires the binding of both factors to a composite Runx1•Ets1 DNA motif. Genome wide analysis for the co-occupancy of Ets1 and Runx1 revealed such composite motifs in a number of genes^[@R6],\ [@R7]^. Among the well-characterized motifs is a GGATGTGG motif of *T cell receptor alpha* (*TCR*α) and *beta* (*TCR*β) gene enhancers^[@R3]-[@R5]^. In our previous studies, we revealed an allosteric mechanism of Runx1 activation by CBFβ^[@R20]^. Here we expand our studies to the mechanism of Ets1 activation by Runx1.

MATERIALS AND METHODS {#S2}
=====================

Construction of plasmids, expression and purification {#S3}
-----------------------------------------------------

The coding region for different Runx1 constructs (Runx1~1-242~, Runx1~48-214~, Runx1~1-214~, Runx1~1-190~ and Runx1~48-242~) were PCR amplified from pVL1392-AML1.FL plasmid and cloned into pET3a vector (Novagen). The resulting constructs were expressed in *E. coli* strain Rosetta-2(DE3) at 18 °C for 16 h following induction with 0.3 mM isopropyl β-D-thiogalactopyranoside (IPTG) at A~600~ = 1. Cells were harvested and resuspended in buffer A (20 mM Tris-HCl pH 7.2, 1 M NaCl, 1 mM ETDA, 10 mM β-mercaptoethanol and 10% glycerol) and lysed with an EmulsiFlex-C5 homogenizer (Avestin). Polyethyleneimine was added to the supernatant at a final concentration of 0.07% and pellet was removed by centrifugation. Proteins were enriched by ammonium sulphate precipitation at 30% saturation. Each pellet was resuspended in buffer A~100~ containing 100 mM NaCl and dialyzed against the same buffer for 3 h. The proteins were purified using HiTrap SP HP (GE Healthcare) followed by HiTrap Heparin HP column (GE Healthcare). Pooled fractions were diluted to half with 1.5 M ammonium sulfate in buffer A~100~ and purified using HiTrap Phenyl HP column (GE Healthcare). Purity of fractions was checked by SDS PAGE and stored at -80 °C.

Single and multiple site mutagenesis protocol^[@R21]^ was used to create point mutants of Runx1. Mutations were first introduced in full-length Runx1 plasmid (pCDN3-Myc3-Runx1) and the resultant mutants were further subcloned in vector pET3a. All mutants were verified by DNA sequencing and were expressed and purified as described above.

Ets1~280-441~ was purified according to reported protocols^[@R22]^. Cloning, expression and purification conditions for Ets1~296-441~ were similar to those of the Ets1~280-441~ protein, except supernatant obtained from 50% ammonium sulfate saturation was used for purification. Coding region for Ets1~276-441~ was cloned in a ligation independent vector in fusion with affinity His~6-~tagged small ubiquitin related modifier (SUMO) protein.^[@R23]^ His~6~-SUMO-Ets1~276-441~ was expressed in *E. coli* strain BL21(DE3) at 37 °C for 5 h following induction with 0.5 mM IPTG at A~600~ = 0.5. Harvested expressed cells were resuspended in 20 mM Tris-HCl pH 7.2, 1 M NaCl, 1 mM β-mercaptoethanol, 5 mM Imidazole and 12% glycerol. Initial treatment for purification of His~6~-SUMO-Ets1~276-441~ was similar to other Ets1 constructs except the pellet obtained by 40-65% of ammonium sulfate fractionation was used for purification. The pellet was resuspended in 20 mM Tris-HCl pH 7.2, 750 mM NaCl, 1 mM β-mercaptoethanol, 5 mM Imidazole and 5% glycerol and purified by HisTrap HP column (GE Healthcare). His~6~-SUMO was cleaved with His~6~-tagged dtUD1 (doubly tagged UD1) protease that was added to protein at 1/5,000 mass ratio and incubated for 3 h at 4 °C before loading onto Ni-IDA column (Bio-Rad). Flow through from the column containing Ets1~276-441~ was collected and stored at -80 °C.

Ets1~276-441~ was phosphorylated using the published protocol^[@R13]^. Peak fractions were pooled and analyzed by SDS-PAGE and MALDI TOF/TOF ([Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}). CaMKIIα used in the kinase reaction was purified according to reported protocol^[@R24]^.

Crystallization and diffraction data collection {#S4}
-----------------------------------------------

Double-stranded *TCRα* enhancer DNA (TCRα) was prepared by annealing synthetic oligonucleotides 5′-GGAAGCCACATCCTCT-3′ and 5′-CAGAGGATGTGGCTTC-3′. Oligonucleotides were purified using Mono Q™ 5/50 GL column (GE Healthcare) and annealed by heating to 95 °C for 5 min and cooling gradually to room temperature. Annealed DNA was purified using Mono Q™ 5/50 GL. The DNA solution was desalted dried and dissolved in 10 mM Tris-HCl pH 7.5.

For Runx1~1-242~•Ets1~296-441~•TCRα complex preparation, the frozen Runx1~1-242~ and Ets1~296-441~ samples were thawed on ice, dialyzed against 10 mM Tris-HCl pH 7.5 and 20 mM DTT buffer and concentrated using Millipore Ultrafree centrifugal devices to 7 and 10 mg•ml^-1^, respectively. At first a Runx1~1-242~•TCRα was prepared and then Ets1~296-441~ was added to reach an equal molar ratio of components. The ternary complex was concentrated up to 7 mg•ml^-1^. The state of sample aggregation at every step was monitored by dynamic light scattering using DynoPro (Wyatt Technology). The Runx1~48-214~•Ets1~296-441~•TCRα complex was prepared in a similar way.

All crystallization screenings were performed by sitting-drop vapor-diffusion method using Natrix screen kit from Hampton Research. Runx1~1-242~•Ets1~296-441~•TCRα produced square-bipyramid and plate shaped crystals in the same drop within 48 hours. Initial crystallization condition was further optimized as 100 mM KCl, 15 mM magnesium chloride hexahydrate, 25 mM MES pH 5.6, 14% v/v PEG MME 550 and 6% v/v glycerol ([Supplementary Fig. 2a](#SD2){ref-type="supplementary-material"}). The size of either crystal was improved by macroseeding after 12 h of equilibration. Growth of the seeded crystals was completed in 10 days ([Supplementary Figs 2b and 2c](#SD2){ref-type="supplementary-material"}). The crystals were cryoprotected in reservoir solutions containing additions of 3% v/v PEG MME 550 and 18% v/v of ethylene glycol for square-bipyramid crystals and 15% v/v of glycerol for plate shaped crystals.

The Runx1~48-214~•Ets1~296-441~•TCRα also produced two types of crystals from the same drop of Natrix crystal screen, one deformed cube type and another rod type. The optimum growth of crystals was achieved from a 2.5% w/v PEG 4000, 5 mM magnesium chloride hexahydrate, 25 mM MES pH 5.6 and 5% v/v glycerol ([Supplementary Figs 2d and 2e](#SD2){ref-type="supplementary-material"}). The cryoprotectant for deformed cube crystals contained additions of 2.5% w/v PEG 4000, 12.5% v/v PEG 200 and 11.5% v/v ethylene glycol. The rod shaped crystals diffracted poorly to 7 Å resolution and were excluded from further studies.

The diffraction data sets were collected using synchrotron radiation at the Advanced Photon Source on the Northeastern Collaborative Access Team beamline BL24ID-E. To minimize the radiation damage, each complete dataset was obtained from one crystal exposed at several different positions. All intensity data were indexed, integrated, and scaled using the HKL2000 program package^[@R25]^ ([Table 1](#T1){ref-type="table"}).

Structure determination and refinement {#S5}
--------------------------------------

The structure of deformed cube crystal was determined by the molecular replacement method starting with the coordinates of ED from Ets1 structure (PDB code 1gvj)^[@R26]^ and RD from Runx1•DNA structure (PDB code 1hjc)^[@R20]^. The asymmetric unit contained two molecules of Runx1~48-214~•Ets1~296-441~•TCRα. Addition of a DNA molecule and major manual rebuilding of the initial model was performed with TURBO-FRODO software. Application of zonal scaling^[@R27]^ and bulk solvent correction improved the quality of electron density maps, enabling EID of Runx1 to be clearly traced and most of the protein side chains to be well fitted. A model was refined using standard protocols. Non-crystallographic two-fold symmetry (NCS) restrains for backbone atoms were applied during the refinement. The structure determination of square-bipyramid and plate shaped crystals was similar to that of cube crystal, but without NCS restraints. The final refinement statistics for all three structures are provided in [Table 1](#T1){ref-type="table"}. CNS version 1.1 was used for all crystallographic computing^[@R28]^. The figures with electron density maps were prepared with TURBO-FRODO software and all remaining figures displaying the protein structures were prepared with PyMol software from Delano Scientific.

SPR experiments {#S6}
---------------

Surface Plasmon Resonance (SPR) studies were performed using Biacore 3000 biosensor system (GE Healthcare) at 25 °C. A 26 bp double stranded DNA corresponding to TCRα enhancer sequence 5′-AAGCAGAAGCCACATCCTCTGGAAAG-3′ with a covalently linked biotin at 5′ end was captured on SA sensor chip (GE Healthcare) at \~100 response units. Just before initiating the experiment, each protein or its mutants were purified through gel filtration column (Superose 12 10/300 GL, GE healthcare) to remove protein aggregates if present. Kinetic runs were conducted at 30 μl•min^-1^ to eliminate mass transport and rebinding artifacts. As analytes, each protein or its mutants were diluted serially in the running buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 2 mM MgCl~2~, 2 mM DTT and 0.005% Tween 20) to concentrations shown in [Supplementary Tables 1-3](#SD2){ref-type="supplementary-material"} and injected over the immobilized ligand surface for 120 sec. For experiments where the binding of one protein was measured in the presence of another, 100 nM of second protein was included in running buffer. Dissociation of analytes was then measured by injecting running buffer or running buffer containing protein. The surface was 'regenerated' with a pulse of 1 M NaCl at the end of each cycle. Duplicate injections of the same concentration in each experiment were superimposable, demonstrating no loss of activity after regenerating the surface. Buffer injection subtracted graphs were analyzed with BIA evaluation version 4.1 using a nonlinear least squares method to obtain the association and dissociation rate constants (*k~a~* and *k~d~*, respectively). For these calculations, the global fitting of the association and dissociation phases of the response curves using a 1:1 binding model was applied. The fittings were considered satisfactory if χ^2^ \< 2. The equilibrium dissociation constants (*K~D~*) were calculated from the equation *K~D~* = *k~d~/k~a~*. Standard deviations were calculated from three experiments.

Transient transfection assays {#S7}
-----------------------------

A 98 bp nucleotide sequence from minimal human *TCRα* enhancer (12-109)^[@R4]^ was cloned upstream to the SV40 promoter in pGL3-Basic vector (where the SV40 promoter is inserted upstream to Luciferase gene). pCDN3-Myc3-Runx1/mutants and pCMV-Tag2a-FlagEts1 were used as an expression vector for Runx1 and Ets1 respectively. Thr286 of pEGFP-C1-CamKIIα was mutated to Asp for constitutive enzymatic activity^[@R24]^. Expression of constitutively active CamKIIα was confirmed by observing the GFP fluorescence in the cells.

Stock cultures of 293T cells were maintained as described earlier^[@R22]^. For transcriptional assays, 293T cells were seeded at 50,000 cells per well of 6-well plates and transfected in duplicate the following day using X-treme gene HP DNA transfection reagent following manufacturer\'s protocol. In addition to 2 μg of the promoter/reporter construct, the cells were cotransfected with 25 ng of pTK-RL (Promega) to normalize for any differences in transfection efficiency. Expression levels of wild type Ets1 and Runx1 as well as Runx1 mutants were determined by transiently transfecting 293T cells separately with expression vector harboring construct for the corresponding protein. To test cooperativity in binding of these proteins, cotransfection of Ets1 and Runx1/mutants was performed. Equal amounts of total DNA in each transfection was maintained by adding empty vector CMV5 as needed. Luciferase activity was measured 48 h after transfection using the Dual-Luciferase Reporter Assay System (Promega).

RESULTS {#S8}
=======

Crystal structures {#S9}
------------------

We crystallized and solved the structures of a ternary complex of Runx1 (residues 1-242), Ets1 (296-441) and 16 base pair DNA fragment of *TCR*α enhancer (Runx1~1-242~•Ets1~296-441~•TCRα) in square-bipyramid and plate crystal forms and also Runx1~48-214~•Ets1~296-441~•TCRα in a deformed cube form ([Table 1](#T1){ref-type="table"}). In all three structures, the ED and RD are bound to respective binding sites positioned opposite relative to each other ([Fig. 1b](#F1){ref-type="fig"} and [Supplementary Figs. 3a, 3b and 3c](#SD2){ref-type="supplementary-material"}). Distributions of temperature factors in these complexes are shown [Supplementary Figs. 3d, 3e and 3f](#SD2){ref-type="supplementary-material"}. The excellent electron density maps of Runx1~48-214~•Ets1~296-441~•TCRα ([Supplementary Figs. 4a and 4b](#SD2){ref-type="supplementary-material"}) unambiguously revealed the structure of residues 189-205 from an Ets1-interaction domain (EID) of Runx1, which includes the helix α1 (194-203). In addition to helix α1, the main-chain tracing of EID helix α2 (204-211) was clearly defined in square-bipyramid Runx1~1-242~•Ets1~296-441~•TCRα crystal ([Supplementary Fig. 4c](#SD2){ref-type="supplementary-material"}). Explanation of the crystal packing effects resulting in disorder of Runx1 Phe194 side-chain in square-bipyramid Runx1~1-242~•Ets1~296-441~•TCRα crystal, in disorder of EID α2 in Runx1~48-214~•Ets1~296-441~•TCRα crystal, and in disorder of an entire EID in Runx1~1-242~•Ets1~296-441~•TCRα plate crystal are provided in [Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}.

Runx1 EID interactions with Ets1 and DNA {#S10}
----------------------------------------

The Runx1 helix α1 is packed on Ets domain parallel to H1 of Ets1, whereas Runx1 α2 is packed parallel to DNA ([Fig. 1b](#F1){ref-type="fig"}). EID interaction buries a total surface area of 1146 Å^2^. The EID•Ets1 interactions are dominated by hydrophobic amino acid residues ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). The EID Phe194, Leu198 and Leu201 side chains are packed into the wide hydrophobic depression at Ets1 surface ([Fig. 2a](#F2){ref-type="fig"}). In addition, EID Arg197 forms a direct hydrogen bond with backbone oxygen of Ets1 Leu422 ([Fig. 2a](#F2){ref-type="fig"}). At the EID•DNA interface, a positively charged area of EID formed by Arg205, Arg206 and Arg208, is positioned against the negatively charged phosphates of DNA ([Fig. 2b](#F2){ref-type="fig"}) providing the long-range protein•DNA electrostatic interactions that further stabilize the structure of EID•Ets1•DNA. In addition, an Arg205 side chain electron density in Runx1~48-214~•Ets1~296-441~•TCRα crystal ([Supplementary Fig. 4a](#SD2){ref-type="supplementary-material"}) indicates a direct interaction of Arg205 with DNA backbone ([Supplementary Fig. 6](#SD2){ref-type="supplementary-material"}).

Runx1 EID displaces the IRM of Ets1 {#S11}
-----------------------------------

The structures of ED and RD and their modes of DNA recognition in Runx1~1-242~•Ets1~296-441~•TCRα complex are consistent with the previously reported crystal structures ([Supplementary Fig. 7](#SD2){ref-type="supplementary-material"}).^[@R22],[@R26],\ [@R29]-[@R33]^ However, a prominent difference exists in folding of IRM within Ets1 that is bound to DNA. The HI1 is unfolded in Ets1•Pax5•DNA and is folded in (Ets1 dimer)•DNA, while HI2 is folded in both complexes ([Supplementary Fig. 8](#SD2){ref-type="supplementary-material"}). In contrast, the entire inhibitory module of Ets1, including IRM, is disordered in Runx1~1-242~•Ets1~296-441~•TCRα. Comparison of Ets1•EID structure from our ternary complex with the solution structure of autoinhibited Ets1^[@R12]^ shows an overlapping of the space occupied by EID of Runx1 and IRM of Ets1 ([Fig. 2c](#F2){ref-type="fig"}). This demonstrates that EID of Runx1 displaces IRM of Ets1. Thus, the crystal structure of Runx1~1-242~•Ets1~296-441~•TCRα provides a novel mechanism of Ets1 cooperative binding to DNA in which the EID of DNA-bound Runx1 displaces the IRM of Ets1 and consequently disrupts the inhibitory function of the residues N-terminal to IRM ([Fig. 3](#F3){ref-type="fig"}). This is consistent with previously reported constitutively active mutants of Ets1 that disrupt the IRM docking to ED and also lead to Ets1 activation.^[@R15]^

Runx1 EID contributes to cooperative binding of Ets1 to DNA {#S12}
-----------------------------------------------------------

To validate the functional relevance and specificity of the observed EID•ED and EID•DNA interactions, we decided to prepare a variety of Runx1 deletions and mutations and analyze their DNA-binding by SPR.

First, we tested DNA binding of Runx1 proteins ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Runx1~1-214~ exhibited 7 fold lower *K*~D~ of 0.47 nM than Runx1~1-242~*K*~D~ of 3.3 nM. These data confirm the presence of autoinhibitory sequences C-terminal to 214.^[@R17]^ However, deletion of 47 residues from N-terminus of Runx1 had little impact of DNA binding (*K*~D~ of Runx1~48-242~ was 2.9 nM). All EID mutants bound DNA with *K*~D~s (2.05 nM to 4.91 nM) that are comparable to *K*~D~ of Runx1~1-214~ (3.3 nM). In summary, all mutated and truncated Runx1 bound to DNA with *K*~D~s less than 5 nM and are useful for studies of Ets1 cooperative binding to the *TCRα* enhancer.

Next, we tested the effect of Runx1 deletions on Ets1 DNA-binding activation ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). *K*~D~ of Ets1 is 30 nM, however in the presence of DNA-bound Runx1~1-242~ the DNA binding activity of Ets1~280-441~ is enhanced 11.5 fold (*K*~D~=2.6 nM). C-terminal truncation of Runx1 up to residue 214 (Runx1~1-214~) had minimal effect on Ets1 activation, which is consistent with the disordered state of residues 213-242 in crystal. In contrast, further C-terminal truncation up to residue 190 (Runx1~1-190~) resulted in a complete loss of Ets1 activation (*K*~D~=34.4 nM). This series of mutants maps the region between 190 and 214 as essential for cooperativity with Ets1, as previously shown.^[@R17]^ Absence of Ets1 activation by Runx1~1-190~ confirms that, in spite of partial overlapping of Ets1 and Runx1 binding sites, the cooperation through DNA effect does not occur and points to a direct participation of EID in the cooperative binding of Ets1 to the *TCRα* enhancer. The absence of cooperation through DNA conformational changes is consistent with the studies by Goetz et al^[@R10]^ using a different approach. In order to eliminate through DNA effect, in their electrophoretic mobility shift assays (EMSA) they used DNA duplexes containing a nick on one strand between the Runx1 and Ets1 binding sites. They found that Runx1 retained Ets1 activation even with a nicked DNA and concluded the absence of Runx1•Ets1 cooperation through changes in DNA conformation.^[@R10]^ In combination, our biochemical and structural data demonstrate that a direct protein interaction explains the cooperative DNA binding between these two factors.

Interaction of Runx1 EID with both Ets1 and DNA is highly specific {#S13}
------------------------------------------------------------------

We analyzed the effect of EID point mutations in its Ets1- and DNA-interacting interfaces ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). We mutated each of three hydrophobic Ets1-interacting amino acid residues Phe194, Leu198 and Leu201 to Ala in Ets1-interacting helix α1 and also prepared double and triple Ala mutants. Furthermore, we introduced a kink in helix α1 by a Ser199Pro mutation. Any of these mutations destabilize EID•Ets1 interaction and result in loss of Ets1 DNA binding activation. To evaluate the contribution of electrostatic interactions between the EID helix α2 and DNA, we prepared the Arg205Glu mutant. As a result, the positive charge reduction in helix α2 prevented the cooperative DNA binding by Ets1. In summary, SPR experiments confirm that interaction of EID with both Ets1 and DNA is highly specific and necessary for activation of Ets1 DNA binding.

Concerted binding of Runx1 and Ets1 to TCRα enhancer {#S14}
----------------------------------------------------

Order of addition DNA binding experiments indicate that Runx1 and Ets1 form a ternary complex with *TCRα* enhancer in a highly concerted manner, consistent with previous observations.^[@R17]^ First, Runx1 binds DNA, and only then does EID recruit Ets1 by binding to ED and displacing the IRM of Ets1. As a consequence, Ets1 becomes active by over 11-fold. In case of reverse order of addition experiments, the *TCRα* enhancer-bound Ets1 was not capable of Runx1 stimulation ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). SPR experiments also show that the addition of CBFβ, a heterodimeric partner of Runx proteins, does not enhance Ets1 recruitment ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). This is in line with the model of Ets1•Runx1•CBFβ•TCRα quaternary complex revealing absence of physical interaction between CBFβ and Ets1 ([Supplementary Fig. 9](#SD2){ref-type="supplementary-material"}). A similar role of CBFβ and "order of addition" effect was observed with Runx1 and Ets1 binding to a so-called SC1/core DNA having different spacing between Runx1 and Ets1 binding sites^[@R10],\ [@R17]^. The Runx1•Ets1 cooperative action in two different composite sites points to a flexibility of the linker between the RD and EID, which is consistent with the disorder of this linker in our crystals.

Runx1 overcomes an inhibitory effect of Ets1 phosphorylation {#S15}
------------------------------------------------------------

Ca^2+^-dependent phosphorylation of serines in the flexible inhibitory region of Ets1 was found to further stabilize the inhibitory conformation and consequently reinforce Ets1 auto-inhibition up to 50 fold.^[@R13],\ [@R15]^ To test whether Runx1 is also capable of overcoming Ets1 autoinhibition after the phosphorylation, we phosphorylated Ets1~276-441~ at two critical sites, Ser282 and Ser285 (Ets1~276-441~\*\*, [Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}). SPR experiments revealed a 14-fold reduction in Ets1~276-441~ DNA-binding affinity after the phosphorylation ([Fig. 4b](#F4){ref-type="fig"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Remarkably, in presence of prebound Runx1~1-242~ or Runx1~1-242~•CBFβ complex, the DNA-binding of Ets1~276-441~\*\* was dramatically enhanced and reached the same order (only about 3-fold less) as a wild type Ets1~276-441~. To the contrary, Ets1~276-441~\*\* DNA-binding was not enhanced in presence of prebound Runx1~1-190~ lacking EID. To confirm that EID is responsible for the enhancement of Ets1~276-441~\*\* DNA binding, we evaluated the effect of single Ser199Pro and double Leu198Ala/Leu201Ala mutations in α2 helix of EID. Both mutations disrupt EID•Ets1 interaction and result in the loss of Ets1~276-441~\*\* DNA binding enhancement. These experiments confirm that Runx1 EID overcomes an inhibitory effect of Ets1 phosphorylation by displacing the IRM of Ets1.

Synergistic trans-activation of TCRα gene by Runx1•Ets1 cooperation {#S16}
-------------------------------------------------------------------

Furthermore, we examined the effect of Runx1 and Ets1 cooperative binding and trans-activation of *TCR*α gene enhancer fragment by transient transfection assay. To determine the impact of Ets1 phosphorylation, the experiments were also performed in presence of constitutively active CaMKIIα. Synergistic trans-activation of *TCRα* gene enhancer was observed both with wild-type and phosphorylated Ets1. However, disrupting EID•Ets1 interaction with Runx1 mutations eliminated the synergy. The results of the SPR ([Fig. 4b](#F4){ref-type="fig"}) and transient transfection ([Fig. 4c](#F4){ref-type="fig"}) experiments provide additional support for a mechanism of Ets1 activation that is based on displacement of an entire N-terminal inhibitory module of either wild type or phosphorylated Ets1 by EID of DNA-bound Runx1 ([Fig. 3](#F3){ref-type="fig"}).

DISCUSSION {#S17}
==========

Comparison of Runx1•Ets1 cooperation with other modes of Ets proteins cooperation {#S18}
---------------------------------------------------------------------------------

Analysis of Runx1•Ets1•TCRα structure and other Ets1 ternary complex crystal structures shows that Ets1 can adopt a variety of different mechanisms for formation of high-order complexes on DNA. For example, Ets1 binds poorly to suboptimal 5′-GGAG-3′ sequence on *mb-1* promoter, however, in presence of Pax5 it binds *mb-1* promoter with high affinity^[@R34]^. Crystal structure of Pax5•Ets1•*mb-1* revealed a direct interaction between DNA-binding domains of Pax5 and Ets1 that altered the DNA-binding surface of Ets1, mainly by conformational switch of its Tyr395 side chain ([Fig. 5a](#F5){ref-type="fig"})^[@R29],\ [@R30]^. Another example is Ets1 cooperative binding to *stromelysin-1* promoter containing palindromic head-to-head Ets-binding sites separated by four base pairs^[@R35]^. Crystal structure shows that cooperative binding to *stromelysin-1* promoter is facilitated by DNA-mediated homodimerization of Ets1 ([Fig. 5b](#F5){ref-type="fig"})^[@R22],\ [@R36]^. Recently we reported also the crystal structure of Ets1 in complex with *TCR*α enhancer DNA^[@R26]^. In this structure Ets1 binds as a homodimer to parallel pieces of dsDNA having Ets-binding sites with opposite orientation ([Fig. 5c](#F5){ref-type="fig"})^[@R26]^. Observation of additional intermolecular Ets1•DNA interactions within this complex ([Fig. 5c](#F5){ref-type="fig"}) indicates that Ets1 binding is cooperative^[@R26]^. Among these Ets1 complexes the most dramatic effect on Ets1 inhibitory IRM-SRR sequences we can see in Runx1•Ets1•TCRα where an IRM is fully disordered. In the Pax5•Ets1•*mb-1* only HI2 of IRM remains bound to Ets domain, however, HI1 is unfolded and partially structured. HI2 remains well folded also in the DNA-bound Ets1 homodimers. Moreover, an Ets domain in these structures also favors the binding of HI1 from a symmetry related molecule.

It is also interesting to compare mechanism of Ets1 activation by Runx1 with the mechanism of activation of another Ets family member, SAP1. Like Ets1, DNA binding of SAP1 is also autoinhibited. SAP1 B-box sequences that are attached by a flexible linker to the C-terminal of Ets domain participate in autoinhibition by interacting with Ets domain. However, SAP1 became active and binds to c-*fos* serum response element (SRE) in presence of serum response factor (SRF)^[@R37],\ [@R38]^. The crystal structure of SAP1•SRF•SRE shows how an autoinhibition of SAP1 was relieved by switching the B-box from Ets domain to the surface of SRF ([Fig. 5d](#F5){ref-type="fig"})^[@R39]^. Furthermore, the cooperative binding is enforced by direct interaction between DNA binding domains of SAP1 and SRF^[@R39],\ [@R40]^. The crystal structures highlight the differences between Ets1 activation by Runx1 and SAP1 activation by SRF. In case of Ets1, binding of Runx1 EID to Ets domain disrupts the autoinhibitory IRM-SRR region packing. However, in case of SAP1 activation its autoinhibitory B-box is moved away from Ets domain by interacting with SRF.

Conclusion {#S19}
----------

Protein-protein interactions and post-translational modifications play an important role in combinatorial regulation of transcription. During different stages of regulation the same transcription factor may interact with different sets of partners. For example, studies of Runx1 partners during different stages of megakaryocytic differentiation revealed its interactions with either GATA, or AP-1 or Ets proteins^[@R41]^. Such a dynamic nature of Runx1 interactions and transcriptional factors in general, often precludes in-depth structural characterization of the underlying mechanisms of action. Here we succeeded in discovery of a novel mechanism of Ets1 activation by DNA-bound Runx1 that involves the displacement of entire inhibitory module of Ets1 by EID of Runx1. Moreover, our data revealed that such displacement efficiently counteracts the strong inhibitory effect of Ets1 phosphorylation. This novel mechanism of phosphorylated Ets1 activation by Runx1 partnership appears to be unique. First, unlike the widely used reversible phosphorylation-dependent regulation of transcription factors^[@R42]^, it does not require Ets1 dephosphorylation. Second, not every Ets1 cooperative DNA binding can overcome the inhibitory effect of Ets1 phosphorylation. For example, contrary to the Runx1•Ets1 partnership, Ets1•Ets1 cooperative binding to palindromic Ets-binding sites on *stromelysin-1* promoter DNA results in additional stabilization of IRM by intermolecular interactions^[@R22]^. However, these Ets1•Ets1 interactions are not capable of counteracting the inhibitory effect of phosphorylation, and upon phosphorylation, Ets1 loses its ability to bind the *stromelysin-1* promoter^[@R35]^. It remains to be seen whether Runx1 is a unique activator of phosphorylated Ets1 or if a variety of other protein partners (e.g. Pax5, AP-1, USF1, etc.)^[@R8]^ are also capable of activating phosphorylated Ets1.
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![Overall structure of ternary complex\
(**a**) Domain organization of full-length Runx1 and Ets1 proteins and their fragments (Runx1~1-242~, Runx1~48-214~ and Ets1~296-441~) used for crystallization. The highlighted domains are: N-terminal, Runt domain (RD), Ets1 interacting domain (EID), transactivation domain (TAD) and repression domain (ReD) for Runx1; and pointed domain (PNT), serine rich region (SRR), inhibition regulatory module (IRM) and ETS domain (ED) for Ets1. The inhibitory helices HI1, HI2 and H4 of IRM are also marked. The red lines within SRR indicate the location of phosphorylation sites. Two dotted lines represent the N terminal of the constructs used for binding studies (Ets1~280-441~ and Ets1~276-441~). *TCRα* enhancer DNA used for crystallization contains Runx1 (green) and Ets1 (blue) binding sites with one overlapping base pair (red). (**b**) Overall structure of Runx1~1-242~•Ets1~296-441~•TCRα in two orientations. Runx1 (green), Ets1 (cyan) and EID of Runx1 (magenta) are drawn as ribbons and DNA is drawn as sticks.](nihms-575621-f0001){#F1}

![EID interactions with Ets1 and DNA\
(**a**) Packing of hydrophobic residues at the EID•Ets1 interface. Ets1 and EID are shown as blue and magenta ribbons. The side chains of participating residues are shown in sticks. An Ets1 surface is semitransparent. A hydrogen bond between EID Arg197 side chain and backbone oxygen of Ets1 Leu422 is also shown here by a dashed line. (**b**) Packing of positively charged area of EID•Ets1 against DNA. On the left the surface calculation includes Ets1 and on the right the surface calculation includes both EID and Ets1. The positively and negatively charged surface areas are in blue and red, respectively. (**c**) Comparison of EID position in Runx1~1-242~•Ets1~296-441~•TCRα (magenta) with the positions of IRM helices HI1 and HI2 in autoinhibited free Ets1 (orange) (PDB access code 1R36) after the superimposition of Ets1 molecules. Ets1 of ternary complex is omitted for clarity.](nihms-575621-f0002){#F2}

![Mechanism of Ets1 activation by Runx1\
(**a**) Ets1 binding to TCRα in the absence of Runx1. Normally, Ets1 is partially inhibited in the absence of Runx1. IRM plays a major role in stabilization of SRR inhibitory confirmation. DNA binding results in disorder of IRM helix HI1 and disruption of SRR inhibitory conformation. Phosphorylation of SRR serines by CamKIIα dramatically enhances an inhibitory conformation of SRR, resulting in a highly inhibited form of Ets1. (**b**) Ets1 binding to TCRα in the presence of DNA-bound Runx1. EID of DNA-bound Runx1 is exposed and disordered. Upon approaching Ets1, EID of Runx1 binds to ED and DNA by forming helices α1 and α2, and displacing both IRM helices HI1 and HI2. This results in disorder of IRM and destabilization of SRR inhibitory confirmation, producing a fully active Ets1. Similar to activation of wild-type Ets1, Runx1 also fully activates the phosphorylated form of Ets1. In both panels, the red stars indicate the presence of phosphorylated serines in SRR.](nihms-575621-f0003){#F3}

![Ets1 activation by Runx1\
(**a**) DNA binding of Ets1~280-441~ to TCRα enhancer DNA in presence of various Runx1 proteins or Runx1•CBFβ~1-141~ complex. (**b**) DNA binding of Ets1~276-441~ and phosphorylated Ets1~276-441~\*\* in presence of various Runx1 proteins or Runx1•CBFβ~1-141~ complex. In panels (a) and (b) the fold of Ets1 DNA binding activation is calculated from the average of dissociation constants obtained from three individual SPR measurements ([Supplementary Tables 2 and 3](#SD1){ref-type="supplementary-material"}). (**c**) Transient transfection assay showing transactivation of *TCR*α enhancer. Luciferase gene expression is driven by *TCR*α gene enhancer in 293T cell in presence and absence of constitutively active CaMKIIα. Fold of activation is calculated relative to the reporter only control. The standard deviations are calculated from three independent experiments with *P* \< 0.05. The reporter construct used is current assay is shown above the graph.](nihms-575621-f0004){#F4}

![High-order complexes of Ets1 and Sap1\
Crystal structures of (**a**) Pax5•Ets1•*mb-1* (PDB code 1mdm), (**b**) (Ets1)~2~•*stromelysin-1* (3mfk), (**c**) (Ets1)~2~•2*TCR*α (3ri4), and (**d**) SAP1•SRF•SRE (1hbx). The areas with intermolecular interactions leading to Ets1 cooperative DNA-binding are circled by dashed red lines. Zoomed area in panel (a) demonstrates a conformational switch of Ets1 Tyr395 side chain induced by interaction with Gln22 of Pax5. The Tyr395 side chain from a superimposed Runx1•Ets1•TCRα is shown in green color.](nihms-575621-f0005){#F5}

###### 

Data collection and refinement statistics.

  Complex                                            Runx1~1-242~•Ets1~296-441~•TCRα   Runx1~48-214~•Ets1~296-441~•TCRα   
  -------------------------------------------------- --------------------------------- ---------------------------------- --------------------------------
  **Data collection**                                                                                                     
                                                                                                                          
  Space group                                        *C*222~1~                         *C*2                               *P*2~1~
  Cell dimensions:                                                                                                        
      *a* (Å)                                        102.622                           87.343                             66.153
      *b* (Å)                                        138.945                           100.140                            100.032
      *c* (Å)                                        98.439                            67.225                             72.064
      *β* (°)                                        90                                120.49                             110.23
  Resolution (Å)^[\*](#TFN1){ref-type="table-fn"}^   50-2.5 (2.54-2.5)                 30-2.7 (2.75-2.7)                  30-2.3 (2.34-2.3)
  Unique reflections                                 24213 (1203)                      13577 (674)                        35376 (1128)
  *R*~merge~ (%)^[\*](#TFN1){ref-type="table-fn"}^   5.6 (43.3)                        4.3 (46.2)                         5.6 (39.2)
  *I*/σ(*I*)                                         29.7 (2.3)                        42.9 (2.1)                         26.7 (2.1)
  Completeness (%)                                   98.0 (98.0)                       98.4 (97.1)                        92.4 (60.3)
  Redundancy                                         2.9 (2.7)                         3.2 (2.5)                          3.2 (2.6)
  Temperature (K)                                    100                               100                                100
  Mosaicity (°)                                      0.28-0.76                         0.79-1.11                          0.59-0.95
                                                                                                                          
  **Refinement**                                                                                                          
                                                                                                                          
  Resolution (Å)                                     29.67-2.5                         29.63-2.7                          29.64-2.3
  No. reflections                                    23493                             13278                              33721
  *R*~work~ / *R*~free~                              22.5/24.5                         22.0/27.2                          23.1/28.0
  No. atoms                                                                                                               
      Runx1/Ets1/DNA                                 988/880/650                       1142/851/650                       2198/1788/1300
      Water/Glycerol                                 66/0                              27/0                               143/6
  Residues in model                                                                                                       
      Runx1                                          50-177                            54-177, 190-212                    53-177, 189-205/52-177,190-204
      Ets1                                           334-437                           332-432                            333-439/332-437
  B-factors (Å^2^)                                                                                                        
      From Wilson plot                               35.1                              44.0                               49.0
      Mean value                                     43.1                              61.7                               52.9
  R.m.s. deviations                                                                                                       
      Bond lengths (Å)                               0.007                             0.007                              0.008
      Bond angles (°)                                1.4                               1.2                                1.4
  Ramachandran plot                                                                                                       
      Favored (%)                                    85.9                              81.3                               88.3
      Allowed (%)                                    13.6                              18.2                               11.0
      Generous (%)                                   0.5                               0.5                                0.7

Values in parentheses are for the last resolution shell.
